Skip directly to content

INFLECTRA® (infliximab) dosing

INFLECTRA (infliximab) dosing is based on a patient`s disease, weight and conditions4

When starting INFLECTRA (infliximab), initial infusions are given at Week 0, 2 and 6 (induction phase). Thereafter, infusions are given every 8 (or 6) weeks (maintenance therapy).4 


*CT-P13 was designed with comparable efficacy, safety and quality to reference infliximab, to increase the treatment options for your Crohn’s disease and ulcerative colitis patients.5,6 Increasing real-world experience confirms the CT-P13 clinical efficacy and safety profile.7

†INFLECTRA® maintenance infusions are given every 6–8 weeks in patients with ankylosing spondylitis. For all other indications, maintenance infusions are given every 8 weeks.


CD, Crohn’s disease; ECCO, European Crohn’s and Colitis Organisation; IBD, Inflammatory bowel disease; OLE, Open-label extension; RCT, Randomised clinical trial; UC, Ulcerative colitis.


1. Gecse KB, et al. J Crohns Colitis 2016;10(2):133-40. 2. Jørgensen KK, et al. Lancet 2017;389:2304-16. 3. QuintilesIMS. MIDAS, February 2017. 4. INFLECTRA® Summary of Product Characteristics. 5. European Public Assessment Report: INFLECTRA™. Available at: Accessed December 2017. 6. European Medicines Agency. Guidelines on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. Available at: 2012/06/WC500128686.pdf. Accessed December 2017. 7. Danese S, et al. J Crohns Colitis 2017;11:26-34.